Cargando…
Bioactive Natural Products against Systemic Arterial Hypertension: A Past 20-Year Systematic and Prospective Review
BACKGROUND: Systemic arterial hypertension is one of the most common cardiovascular risks, corresponding to 45% of deaths involving CVDs. The use of natural products, such as medicinal plants, belongs to a millennial part of human therapeutics history and has been employed as an alternative anti-hyp...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236778/ https://www.ncbi.nlm.nih.gov/pubmed/35769156 http://dx.doi.org/10.1155/2022/8499625 |
_version_ | 1784736608184958976 |
---|---|
author | da Silva, Maisa Gomes Barbosa, Sara Léa Fortes Silva, Diego Santos Bezerra, Isadora Basílio Meneses Alves Bezerra, Érika Coelho, Angélica Gomes Pinheiro da Silva Morais, Ilmara Cecília Rezende-Júnior, Luis Mário do Carmo, Iolanda Souza Lima-Neto, José de Sousa Comerma-Steffensen, Simón Gabriel Citó, Antônia Maria das Graças Lopes Arcanjo, Daniel Dias Rufino |
author_facet | da Silva, Maisa Gomes Barbosa, Sara Léa Fortes Silva, Diego Santos Bezerra, Isadora Basílio Meneses Alves Bezerra, Érika Coelho, Angélica Gomes Pinheiro da Silva Morais, Ilmara Cecília Rezende-Júnior, Luis Mário do Carmo, Iolanda Souza Lima-Neto, José de Sousa Comerma-Steffensen, Simón Gabriel Citó, Antônia Maria das Graças Lopes Arcanjo, Daniel Dias Rufino |
author_sort | da Silva, Maisa Gomes |
collection | PubMed |
description | BACKGROUND: Systemic arterial hypertension is one of the most common cardiovascular risks, corresponding to 45% of deaths involving CVDs. The use of natural products, such as medicinal plants, belongs to a millennial part of human therapeutics history and has been employed as an alternative anti-hypertensive treatment. OBJECTIVE: The present review aims to prospect some natural products already experimentally assayed against arterial hypertension through scientific virtual libraries and patent documents over the past 20 years. Search strategy. This is a systematic review of the adoption of the PRISMA protocol and a survey of the scientific literature that synthesizes the results from published articles between 2001 and 2020 concerning the use of medicinal plants in the management of hypertension, including which parts of the plant or organism are used, as well as the mechanisms of action underlying the anti-hypertensive effect. Furthermore, a technological prospection was also carried out in patent offices from different countries in order to check technologies based on natural products claimed for the treatment or prevention of hypertension. Inclusion criteria. Scientific articles where a natural product had been experimentally assayed for anti-hypertensive activity (part of plants, plant extracts, and products derived from other organisms) were included. Data extraction and analysis. The selected abstracts of the articles and patent documents were submitted to a rigorous reading process. Those articles and patents that were not related to anti-hypertensive effects and claimed potential applications were excluded from the search. RESULTS: Eighty specimens of biological species that showed anti-hypertensive activity were recovered, with 01 representative from the kingdom Fungi and 02 from the kingdom Protista, with emphasis on the families Asteraceae and Lamiaceae, with 6 representatives each. Leaves and aerial parts were the most used parts of the plants for the extraction of anti-hypertensive products, with maceration being the most used extraction method. Regarding phytochemical analyses, the most described classes of biomolecules in the reviewed works were alkaloids, terpenes, coumarins, flavonoids, and peptides, with the reduction of oxidative stress and the release of NO among the mechanisms of action most involved in this process. Regarding the number of patent filings, China was the country that stood out as the main one, with 813 registrations. CONCLUSION: The anti-hypertensive activity of natural products is still little explored in Western countries. Besides, China and India have shown more results in this area than other countries, confirming the strong influence of traditional medicine in these countries. |
format | Online Article Text |
id | pubmed-9236778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-92367782022-06-28 Bioactive Natural Products against Systemic Arterial Hypertension: A Past 20-Year Systematic and Prospective Review da Silva, Maisa Gomes Barbosa, Sara Léa Fortes Silva, Diego Santos Bezerra, Isadora Basílio Meneses Alves Bezerra, Érika Coelho, Angélica Gomes Pinheiro da Silva Morais, Ilmara Cecília Rezende-Júnior, Luis Mário do Carmo, Iolanda Souza Lima-Neto, José de Sousa Comerma-Steffensen, Simón Gabriel Citó, Antônia Maria das Graças Lopes Arcanjo, Daniel Dias Rufino Evid Based Complement Alternat Med Review Article BACKGROUND: Systemic arterial hypertension is one of the most common cardiovascular risks, corresponding to 45% of deaths involving CVDs. The use of natural products, such as medicinal plants, belongs to a millennial part of human therapeutics history and has been employed as an alternative anti-hypertensive treatment. OBJECTIVE: The present review aims to prospect some natural products already experimentally assayed against arterial hypertension through scientific virtual libraries and patent documents over the past 20 years. Search strategy. This is a systematic review of the adoption of the PRISMA protocol and a survey of the scientific literature that synthesizes the results from published articles between 2001 and 2020 concerning the use of medicinal plants in the management of hypertension, including which parts of the plant or organism are used, as well as the mechanisms of action underlying the anti-hypertensive effect. Furthermore, a technological prospection was also carried out in patent offices from different countries in order to check technologies based on natural products claimed for the treatment or prevention of hypertension. Inclusion criteria. Scientific articles where a natural product had been experimentally assayed for anti-hypertensive activity (part of plants, plant extracts, and products derived from other organisms) were included. Data extraction and analysis. The selected abstracts of the articles and patent documents were submitted to a rigorous reading process. Those articles and patents that were not related to anti-hypertensive effects and claimed potential applications were excluded from the search. RESULTS: Eighty specimens of biological species that showed anti-hypertensive activity were recovered, with 01 representative from the kingdom Fungi and 02 from the kingdom Protista, with emphasis on the families Asteraceae and Lamiaceae, with 6 representatives each. Leaves and aerial parts were the most used parts of the plants for the extraction of anti-hypertensive products, with maceration being the most used extraction method. Regarding phytochemical analyses, the most described classes of biomolecules in the reviewed works were alkaloids, terpenes, coumarins, flavonoids, and peptides, with the reduction of oxidative stress and the release of NO among the mechanisms of action most involved in this process. Regarding the number of patent filings, China was the country that stood out as the main one, with 813 registrations. CONCLUSION: The anti-hypertensive activity of natural products is still little explored in Western countries. Besides, China and India have shown more results in this area than other countries, confirming the strong influence of traditional medicine in these countries. Hindawi 2022-06-20 /pmc/articles/PMC9236778/ /pubmed/35769156 http://dx.doi.org/10.1155/2022/8499625 Text en Copyright © 2022 Maisa Gomes da Silva et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article da Silva, Maisa Gomes Barbosa, Sara Léa Fortes Silva, Diego Santos Bezerra, Isadora Basílio Meneses Alves Bezerra, Érika Coelho, Angélica Gomes Pinheiro da Silva Morais, Ilmara Cecília Rezende-Júnior, Luis Mário do Carmo, Iolanda Souza Lima-Neto, José de Sousa Comerma-Steffensen, Simón Gabriel Citó, Antônia Maria das Graças Lopes Arcanjo, Daniel Dias Rufino Bioactive Natural Products against Systemic Arterial Hypertension: A Past 20-Year Systematic and Prospective Review |
title | Bioactive Natural Products against Systemic Arterial Hypertension: A Past 20-Year Systematic and Prospective Review |
title_full | Bioactive Natural Products against Systemic Arterial Hypertension: A Past 20-Year Systematic and Prospective Review |
title_fullStr | Bioactive Natural Products against Systemic Arterial Hypertension: A Past 20-Year Systematic and Prospective Review |
title_full_unstemmed | Bioactive Natural Products against Systemic Arterial Hypertension: A Past 20-Year Systematic and Prospective Review |
title_short | Bioactive Natural Products against Systemic Arterial Hypertension: A Past 20-Year Systematic and Prospective Review |
title_sort | bioactive natural products against systemic arterial hypertension: a past 20-year systematic and prospective review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236778/ https://www.ncbi.nlm.nih.gov/pubmed/35769156 http://dx.doi.org/10.1155/2022/8499625 |
work_keys_str_mv | AT dasilvamaisagomes bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT barbosasaraleafortes bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT silvadiegosantos bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT bezerraisadorabasiliomeneses bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT alvesbezerraerika bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT coelhoangelicagomes bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT pinheirodasilvamoraisilmaracecilia bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT rezendejuniorluismario bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT docarmoiolandasouza bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT limanetojosedesousa bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT comermasteffensensimongabriel bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT citoantoniamariadasgracaslopes bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview AT arcanjodanieldiasrufino bioactivenaturalproductsagainstsystemicarterialhypertensionapast20yearsystematicandprospectivereview |